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Abstract
Background: Loss of neural function is a critical but unsolved issue after cerebral ischemia insult. Neuronal
plasticity and remodeling are crucial for recovery of neural functions after brain injury. Buyang Huanwu decoction,
which is a classic formula in traditional Chinese medicine, can positively alter synaptic plasticity. This study
assessed the effects of Buyang Huanwu decoction in combination with physical exercise on neuronal plasticity in
cerebral ischemic rats.
Methods: Cerebral ischemic rats were administered Buyang Huanwu decoction and participated in physical
exercise after the induction of a permanent middle cerebral artery occlusion. The neurobehavioral functions and
infarct volumes were evaluated. The presynaptic (SYN), postsynaptic (GAP-43) and cytoskeletal (MAP-2) proteins in
the coronal brain samples were evaluated by immunohistochemistry and western blot analyses. The ultrastructure
of the neuronal synaptic junctions in the same region were analyzed using transmission electron microscopy.
Results: Combination treatment of Buyang Huanwu decoction and physical exercise ameliorated the neurobehavioral
deficits (p < 0.05), significantly enhanced the expression levels of SYN, GAP-43 and MAP-2 (p < 0.05), and maintained
the synaptic ultrastructure.
Conclusions: Buyang Huanwu decoction facilitated neurorehabilitation following a cerebral ischemia insult through an
improvement in synaptic plasticity.
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Background
Cerebral ischemia is a major cause of adult mortality
and morbidity in developed countries [1–3]. Although
numerous drugs and therapies have been tested, there
is no effective treatment that dramatically attenuates
the neural deficits after stroke in the clinical setting.
Because the central nervous system (CNS) of adult
mammals has limited self-repair or regeneration, a
CNS injury inevitably results in a loss of neural func-
tion [4, 5]. Neuronal plasticity and remodeling are
critical processes that underlie normal CNS function
[6]. The CNS can facilitate the neuronal plasticity in-
duced by brain injury [7]. The decreased synaptic
activity after brain injury leads to increased presynap-
tic release of neurotransmitters, as well as upregulated
postsynaptic response to those neurotransmitters; this
can, at least in part, restore neural function following
an injury [8]. In addition to synaptic activity regula-
tion, new synapse formation, which may compensate
for the lost structural circuits, can be triggered by
stroke [9–12]. This self-regulation of synaptic
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plasticity is activity- and experience-dependent [7].
Physical exercise improves the neurological impair-
ments that follow brain insults [13–15]. In synaptic
mechanism studies, the beneficial effects of physical
exercise were correlated with the maintenance of pre-
and postsynaptic components [16, 17].
Pharmacological compounds can assist the recovery
from stroke and other CNS diseases [18–20]. Numerous
pharmaceutical drugs have been studied, but few have
dramatically positive results. The Buyang Huanwu de-
coction (BYHWD) has been utilized for hundreds of
years to improve the recovery of neurological function
in stroke-induced disabilities in China [21]. This formu-
lation consists of: Radix Astragali, the root of Astragalus
membranaceus (Fisch.) Bge. var. mongholicus (Bge.)
Hsiao; Radix Angelicae Sinensis, the root of Angelica
sinensis (Oliv.) Diels; Radix Paeoniae Rubra, the root of
Paeonia lactiflora Pall.; Chuanxiong Rhizoma, the root
and rhizome of Ligusticum chuanxiong Hort.; Semen
Persicae, the seed of Prunus persica (L) Batsch; Flos
Carthami, the flower of Carthamus tinctorius L. and
Pheretima, the dried body of Pheretima aspergillum (E.
Perrier) [22, 23], The protective mechanisms underlying
this classic traditional Chinese formula includes the
stimulation of neural proliferation, the modulation of
VEGF and Flk1 expression levels, alterations in glutam-
ate levels, and a selective decrease of some amino acids
in the cerebrospinal fluid [4, 22, 24]. BYHWD was also
testified to be neuroprotective in the cerebral ische-
mic models in many other studies. A study reported
oral administration of BYHWD inhibits caspase-3 and
neuron apoptosis in the hippocampal CA1 region of
Wistar rats following four-vessel occlusion (4-VO)
[25]. Intragastric administration of BYHWD down-
regulates inflammation, apoptosis and angiogenesis, as
well as up-regulates neurogenesis and nervous system
development in cerebral ischemia/reperfusion (CI/R)
injured mice and rats [21, 22]. Despite its clinical and
laboratory effectiveness, the functional recovery using
BYHWD following cerebral ischemia has not been
fully investigated. It is difficult to draw a definite con-
clusion on safety of BYHWD, admittedly, BYHWD
seems well tolerable to all patients in clinically [26].
In addition, the safety of BYHWD on patients with acute
cerebral ischemia has been testified in a Chinese clinical
trial [27].
In this study, we evaluated the combination of
BYHWD and physical exercise in cerebral ischemic
rats, which had a permanent middle cerebral artery oc-
clusion. We assessed the therapeutic effects of this
combination therapy by measuring neurobehavioral
functions and infarct volumes, analyzing the SYN,




The animal handling was approved by the Institutional
Animal Care and Use Committee (IACUC) of the
Guangdong Provincial Hospital of Chinese Medicine,
Guangzhou, China. This experimental protocol is in
agreement with the European Community guidelines
(EEC Directive of 1986; 86/609/EEC). Adult male
Sprague-Dawley rats were provided by the Medical
Laboratory Animal Centre of Guangdong (Guangzhou,
China). The animals (250–300 g) were housed in an ani-
mal room (12:12 h light/dark circle; 22–24 °C) with free
access to food and water.
Induction of the permanent middle cerebral artery
occlusion (MCAO)
The animals were anesthetized with ketamine (100 mg/kg;
Gu-Tian Pharmaceutical Co., Ltd.; Fujian, China) and
xylazine (10 mg/kg; Sigma-Aldrich; St. Louis, MI, USA).
The animals’ temperature was maintained at 37.0 ± 0.5 °C
using a heating pad (RWD Life Science; Shenzhen, China).
The animals were placed in a supine position after
anesthesia. Subsequently, under an operating microscope
(Carl-Zeiss; Jena, Germany), a midline incision was made
in the neck of the experimental subject. The right com-
mon carotid artery (CCA), external carotid artery (ECA)
and internal carotid artery (ICA) were isolated. The ECA
was cut approximately 5 mm above the common carotid
artery bifurcation. We inserted a 4–0 suture (20 mm; Der-
malon, 1744–31; Covidien; OH, USA) coated with silicone
rubber (3 mm length, 0.4 mm diameter; Heraeus Kulzer;
Hanau, Germany) into the ECA stump, where it was re-
versed into the ICA and finally to the ostium of the mid-
dle cerebral artery (MCA) (approximately 15 mm from
the carotid bifurcation), as reported previously [28–30].
The 4–0 suture coated with silicone rubber is displayed in
Fig. 1a.
The laser Doppler flowmetry (LDF) analysis for the
measurement of the surface cerebral blood flow (CBF)
A successful occlusion was confirmed by monitoring the
cerebral blood flow (CBF) in the ipsilateral cortex. The
measurement of the surface CBF was conducted by a
laser Doppler flowmetry (LDF) (Moor Instruments;
Axminster, UK) during the MCAO induction, as previ-
ously described [31, 32]. In order to determine the sur-
face CBF that was supplied by the bilateral MCA, 2 burr
holes (ID =2 mm) were drilled 2.5 mm to the left and
right, and 1.0 mm posterior to bregma, as previously de-
scribed [31, 32]. When the value of the ipsilateral CBF
decreased to 1/3 of the baseline value, the MCA was
considered to be successfully occluded.
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Buyang Huanwu decoction (BYHWD) preparation
The ingredients of BYHWD including Radix Astragali,
Radix Angelicae Sinensis, Radix Paeoniae Rubra,
Chuanxiong Rhizoma, Semen Persicae, Flos Carthami
and Pheretima were mixed together at a ratio of
120:10:10:10:10:10:4.5 (dry weight). It was prepared as
previously reported [4, 21]. All dried, crude drugs were
ordered from Kang Mei Pharmaceutical Co., Ltd. (Puning,
Guangdong, China) and were identified by the Depart-
ment of Pharmacology at Guangdong Provincial Hospital
of Chinese Medicine. To maintain the consistency of the
herbal chemical ingredients, all herbs in this decoction
were obtained from their original sources. The extrac-
tion procedure was performed according to the Chin-
ese Pharmacopoeia. The details of the BYHWD
ingredients were listed in Table 1, while the chemical
fingerprints of the BYHWD ingredients were shown in
the Additional file 1. The BYHWD was made by boiling
the dried ingredients in distilled water at 100 °C for
30 min. A freeze-dried drug solution was subsequently
made, and the BYHWD powder was produced under
vacuum. The powder was dissolved in distilled water at
a final concentration of 2.0 g/ml, which is equivalent to
the dry weight of the raw materials.
Fig. 1 Laboratory techniques used in this study. A 4–0 suture coated with silicone rubber (a) was used for the MCAO induction. A programmable
and motorized running wheel apparatus (b) was employed for the physical exercises post-cerebral ischemia. The design of this study (c). The
intragastric administration of BYHWD began 2 h after the MCAO induction and was administered daily from Day 1 to 14 or until euthanasia. The
physical exercises began on Day 3 post-ischemia and ended on Day 14 or euthanasia. The analytic modalities (neurobehavioral assessment,
immunohistochemistry, and western blot) were performed on Day 3, 7 and 14 after the MCAO induction. Other techniques (TTC and TEM) were
performed on Day 3 or 14 after the MCAO induction. BYHWD, Buyang Huanwu decoction; IHC, immunohistochemistry; MCAO, middle cerebral artery
occlusion; NBA, neurobehavioral assessment; TEM, transmission electron microscope; TTC, triphenyltetrazolium chloride staining; WB, western-blot
Table 1 Ingredients of BYHWD
Components (Latin name) Family Voucher specimen No. Part used processing
Plants
Radix Astragali Leguminosae 130,401,831 Root Extraction
Radix Angelicae Sinensis Umbelliferae 130,504,671 Root Extraction
Radix Angelicae Sinensis Ranunculaceae 130,409,121 Root Extraction
Radix Paeoniae Rubra Umbelliferae 130,509,661 Root and rhizome Extraction
Semen Persicae Rosaceae 130,308,751 Seed Extraction
Flos Carthami Composite 130,314,541 Flower Extraction
Insects
Pheretima Megascolecidae 130,608,701 Dried body Farina
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Physical exercise
To quantify the physical exercise intensity, a programmable
and motorized wheel apparatus (21 cm in diameter, 40 cm
in length; Fig. 1b) was used. For pre-conditioning, the ani-
mals used the running wheel for exercise for 7 days prior to
the MCAO induction. On the first day, the rats ran in the
wheel at a speed of 5 revolutions (rev)/min (approximately
3 m/min). The speed of the wheel gradually increased to 10
rev/min (approximately 6 m/min) on Day 7, as reported
previously [13, 33].
Animal groups and study design
The rats were randomly divided into 5 groups: 1) the sham
group (n = 24), 2) the MCAO group (n = 38), 3) the
MCAO + BYHWD group (n = 35), 4) the MCAO + physical
exercise (PE) group (n = 36), and 5) the
MCAO + BYHWD + PE group (n = 29). Before MCAO in-
duction, the rats from the MCAO + PE and MCAO+
BYHWD + PE groups participated in physical exercise with
the running wheel, as described above. The animals from
the MCAO, MCAO + BYHWD, MCAO + PE and
MCAO + BYHWD + PE groups underwent the permanent
MCAO procedure. The sham group animals were given a
sham surgery, which was identical to the MCAO induction
procedure, without inserting the 4–0 silicone-coated nylon
monofilament. The rats from the MCAO + BYHWD and
MCAO + BYHWD + PE groups were administered
BYHWD (20 g/kg) by intragastric administration. The
medication began 2 h after the MCAO induction and was
administered daily from 1 to 14 days or until euthanasia.
The physical exercises were performed daily from 3 to
14 days post-ischemia in the MCAO+ BYHWD + PE
group. The pattern of physical exercises were identical to
the previous studies [13, 33].
According to previous study [22], we chose 10–40 g/kg
as the dosage of BYHWD in the preliminary study (Cai J,
Pan R, Xu D, Wang B, Zhou M, Chen H. unpublished
data). We found that the neuroprotective effects (neurobe-
havioral assessments) in dosage of 20–40 g/kg were better
than those in dosage of 10 g/kg. Therefore, the dosage of
20 g/kg was chosen in present study. In addition, we
did not found any obvious side-effects in dosage of 10–
40 g/kg in preliminary study (Cai J, Pan R, Xu D, Wang
B, Zhou M, Chen H. unpublished data).
A subset of rats from all groups (n = 6 at each time point)
underwent a neurobehavioral assessment on Day 3, 7 and
14 post-ischemia, and were then euthanized by decapitation
for triphenyltetrazolium chloride (TTC) staining and infarct
volume calculations (n = 5 on Day 3), immunohistochemi-
cal assays (n = 4 on Days 3, 7 and 14), western blot analyses
(n = 6 on Days 3, 7 and 14) and transmission electron
microscopic (TEM) examinations (n = 5 at Day 14). The
experimental design was shown in Fig. 1c.
Neurobehavioral assessment
We adopted a scale of 0–18 (normal score, 0; maximal
deficit score, 18) for the neurobehavioral measurement
to assess the neurological deficits on Days 3, 7 and 14
after the MCAO induction [33–35]. The neurological se-
verity score was a combination of motor, sensory, reflex
and balance tests. The details of the neurobehavioral as-
sessment were displayed in Additional file 2.
Infarct volume quantification
After euthanasia, the brains were extracted. The brain
tissue was sliced into 2 mm cross-sections using a rat
brain matrix (RWD, Life Science). The slices were incu-
bated in a 2% solution of 2,3,5-TTC (Sigma-Aldrich; St
Louis, MO, USA) at 37 °C for 20 min. The sample sec-
tions were photographed and analyzed by an observer
blind to the group assignment using Image J software
(NIH Program; Bethesda, MD, USA). The infarct vol-
umes were calculated according to previously described
methods [36].
Immunohistochemical assay
Animals were euthanized and transcardially perfused
with saline and 4% paraformaldehyde. The brains were
removed and stored in 4% paraformaldehyde for 24 h.
The brain sections (3 μm) were fixed in 4% paraformal-
dehyde for 5 min, and then washed and blocked for
30 min in 10% (w/v) bovine serum albumin dissolved in
0.1 M phosphate buffer saline (PBS). The sections were
incubated at 4 °C overnight with the primary antibodies
against SYN (SYN-1; 1:200 dilution; Cell Signaling Tech-
nology; Beverly, MA, USA), GAP-43 (1:200 dilution;
Abcam; Cambridge, MA, USA) and MAP-2 (1:200 dilu-
tion; Santa Cruz Biotechnology; Dallas, TEX, USA),
followed by an incubation with the corresponding Alexa
Fluor 568 secondary antibody (goat anti-rabbit; 1:200 di-
lution; Abcam) at room temperature for 1 h. After wash-
ing in PBS, the coverslips were mounted on glass slides
with 4,6-diamidino-2-phenylindole (DAPI;1:1000 dilu-
tion; Sigma-Aldrich).
Western blot analysis
The frozen brain samples were lysed with a buffer
containing 20 mM Tris (pH 7.6), 0.2% SDS, 1% TritonX-
100, 1% deoxycholate, 1 mM phenylmethylsulfonyl fluor-
ide, and 0.11 IU/mL aprotinin. All the ingredients were
purchased from Sigma-Aldrich. The total protein was
extracted from the brain samples and subjected to an 8%
SDS-PAGE. The following antibodies were used: poly-
clonal antibodies against SYN (SYN-1; 1:1000 dilution;
Cell Signalling Technology), GAP-43 (1:1000 dilution;
Abcam), MAP-2 (1:1000 dilution; Santa Cruz Biotech-
nology) and β-actin (1:6000 dilution; Sigma-Aldrich).
The densitometry analyses of the western blots were
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performed with Glyko Bandscan software (Glyko; No-
vato, CA, USA). The experiments were conducted at
least 3 times.
TEM examination
The animals were euthanized and transcardially perfused
with 50 ml of saline followed by 100 ml of 4% paraformal-
dehyde and 2.5% glutaraldehyde in 0.1 mol/l cacodylic
acid buffer (pH 7.3). Following an ethanol series, the fixed
brain tissues (right frontal lobe) were dehydrated and em-
bedded in an epoxy resin. Next, the samples were cut into
ultrathin sections, which were subsequently mounted on
copper grids and stained in uranyl acetate and citric acid
lead. The prepared samples were imaged using a H-7650
transmission electron microscope (Hitachi; Tokyo, Japan).
Statistical analyses
The data are shown as the means ± the standard error
of the means (SEMs). A one-way analyses of variance
(ANOVA) followed by a Student, Newman–Keuls or
Dunnett’s post-hoc test, were utilized for the compari-
sons between more than 2 groups. SPSS 18.0 (SPSS;
Chicago, IL, USA) was used for the statistical analyses,
and the statistical significance was set at p < 0.05.
Results
Combination treatment of BYHWD and physical exercise
decreased the mortality and ameliorated the neurological
deficits
Seventy-two hours after MCAO induction, the mortality
rates varied among the 4 groups: 23.7% (9/38) in the
MCAO group, 17.1% (6/35) in the MCAO + BYHWD
group, 22.2% (8/36) in the MCAO + PE group, and 13.8%
(4/29) in the MCAO + BYHWD + PE group (Fig. 2a). The
mortality of the MCAO + BYHWD + PE group was lower
than the other 3 groups.
On Days 3, 7, 14 post-ischemia, the neurological defi-
cits of all groups were assessed using an 18-point sys-
tem. A higher score indicated more deficits. We found
that the MCAO group exhibited severe deficits
(9.2 ± 0.6, 8.6 ± 0.7 and 7.2 ± 0.6 on Days 3, 7 and 14
post-ischemia, respectively). The MCAO + BYHWD
group (9.4 ± 0.7, 7.6 ± 0.7 and 6.0 ± 0.5 on Days 3, 7
and 14 post-ischemia, respectively) and MCAO + PE
group (9.3 ± 0.6, 7.4 ± 0.7 and 6.1 ± 0.5 on Days 3, 7
and 14 post-ischemia, respectively) exhibited moderate
deficits. Noticeably, the MCAO + BYHWD + PE group
exhibited milder neurological deficits at each time point
relative to the other MCAO groups (9.2 ± 0.6, 6.9 ± 0.6
and 5.1 ± 0.5 on Days 3, 7 and 14 post-ischemia, re-
spectively; Fig. 2b).
Combination treatment of BYHWD and physical exercise
did not reduce infarct volumes
To determine whether combination treatment was neuro-
protective, the infarct volumes of all groups were examined
at each time point following the cerebral ischemia. The
TTC-stained slices of the coronal brain sections were used
to confirm the presence of successful cerebral infarctions in
the MCAO induction animals. The representative examples
were displayed in Fig. 3a. After TTC staining, the brain sec-
tions of sham group were uniformly stained a dark red and
had no pale infarct area. On Day 3 post-ischemia, the
infarct volumes in the MCAO, MCAO + BYHWD,
MCAO + PE and MCAO + BYHWD + PE groups were
299.3 ± 8.5, 287.4 ± 7.6, 302.1 ± 11.5, 292.6 ± 7.2 mm3 re-
spectively. There were no significant differences in the
infarct volumes between these 4 groups (p > 0.05; Fig. 3b).
Fig. 2 Comparisons of the mortalities and neurobehavioral assessment in all groups. Mortalities of all groups (a). Evaluations of the neurological
deficits in all groups (n = 6 at each time point) (b). Scores of neurological deficits are expressed as the means ± standard error of the means; ns,
not significant, p > 0.05; *, p < 0.05, compared to the MCAO group
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Combination treatment increased SYN, GAP-43 and MAP-
2 protein levels after cerebral ischemia
Immunohistochemistry and western blots were
employed to detect and quantify SYN (SYN-1), GAP-43
and MAP-2 protein levels. The immunohistochemical
micrographs revealed that SYN, GAP-43 and MAP-2
proteins were normally expressed in the brain samples
from sham group (Fig. 4A-a, B-a, C-a). However, in the
micrographs of the peri-infarct zones from the MCAO
group, the protein expression levels were dramatically
reduced (Fig. 4A-b, B-b, C-b). The disruption of these
proteins was mildly attenuated in the MCAO + BYHWD
group (Fig. 4A-c, B-c, C-c) and the MCAO + PE group
(Fig. 4A-d, B-d, C-d). The positive staining measure-
ment of immunohistochemical micrographs were ana-
lyzed with Image J software (NIH Program, Bethesda,
Maryland, USA). However, the positive staining meas-
urement of SYN slices were employed relative intensity
calculation technique as previously reported [37]. In
the sections from the MCAO + BYHWD + PE group
(Fig. 4A-e, B-e, C-e), the expression levels of these pro-
teins were distinctly upregulated compared to the levels
in the MCAO group (p < 0.05).
Western blot analyses revealed that the protein expres-
sion levels of SYN (SYN-1), GAP-43 and MAP-2 in the
sham group were detectable. These protein expression
levels were remarkably reduced in the MCAO group
post-ischemia compared to the levels of the sham group
(p < 0.05). However, the decreased levels of these pro-
teins were ameliorated to a certain extent after the
MCAO induction in the MCAO + BYHWD and
MCAO + PE group, although not statistically significant
(p > 0.05). In the MCAO + BYHWD + PE group, these
proteins were distinctly up-regulated compared to the
expression levels in the MCAO group (p < 0.05). The
representative western blot micrographs were displayed
in Fig. 5a, and the relative expression levels of SYN,
GAP-43 and MAP-2 are disclosed in Fig. 5b.
Combination treatment maintained the ultrastructural
integrity of the synapse
TEM technique was used to analyze the ultrastructural
changes of the synapse post-ischemia. The ultrastructure
of the synapse in the sham group remained intact and
clear. In the MCAO group, the axons and dendrites
were chaotic, and there were no proper synapses in the
peri-infarct region. In the MCAO + BYHWD and
MCAO + PE groups, the axonal and dendritic mem-
branes and the synaptic structures were healthier and
more intact compared to the morphology found in the
MCAO group. However, in the MCAO + BYHWD + PE
group, the synaptic ultrastructure looked similar to the
sham group’s ultrastructure, although there were some
indistinct axons and dendritic membranes. The repre-
sentative TEM micrographs were shown in Fig. 6.
Discussion
The recovery after a CNS injury requires cortical plasti-
city, including synaptic plasticity [6, 7, 38]. Cerebral
plasticity is influenced by many factors. Activity- and
experience-dependent plasticity is very important for
cerebral plasticity in both normal and injured CNS [10].
One treatment protocol that persistently induces a post-
stroke behavioral recovery is the forced use of the
Fig. 3 Representative TTC-stained slices and the infarct volumes in all groups. Representative TTC-stained slices of the coronal brain sections (a)
from all groups exhibit the pale infarct area induced by a permanent MCAO. The infarct volumes in all groups on Day 3 after the MCAO induction
(n = 5) (b). The bars indicate the means ± the standard errors of the means; ns, p > 0.05; *, p < 0.05, relative to the MCAO group
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disabled limbs in a patterned or task-specific behav-
ioral activity task [7, 39–42]. This treatment strategy
was developed using the theory of activity- and
experience-dependent plasticity for the rehabilitation
of the affected limbs. However, one treatment modal-
ity is unable to meet the extensive rehabilitative needs
after stroke. Thus, pharmacological neuromodulation
may lead to a significant improvement in rehabilitative
outcomes [18, 43–45]. However, few drugs have been
effective in facilitating physical rehabilitation. Buyang
Huanwu decoction (BYHWD) is believed to be an im-
portant promoter in neurorehabilitation after stoke
[27]. In this study, BYHWD was evaluated in synaptic
plasticity.
According to Fig. 2a, the survival rates varied among
the 4 MCAO groups. The mortalities of the 2 groups
that were administered BYHWD were lower than the
other MCAO groups. This finding agrees with a previ-
ous study [21]. However, the mortality rates of the
MCAO mice reported by that study were approxi-
mately 50–83%, leading to a discrepancy in the total
mortality between that study and the results presented
here. This may be due to the anatomical variations of
the posterior communicating artery in the MCAO
mice, which can be optimized in future studies [46]. In
this study, the physical exercise treatment was added
after 3 days of cerebral ischemia. A neurobehavioral
assessment scale was employed to evaluate the
Fig. 4 High magnification micrographs of the immunohistochemical fluorescent labeling of SYN (SYN-1), GAP-43 and MAP-2. The immunohistochemistry
micrographs display the locations of the SYN (a), GAP-43 (b) and MAP-2 (c) proteins in sham (a), MCAO (b), MCAO + BYHWD (c), MCAO + PE (d) and
MCAO + BYHWD + PE (e) groups. The scale bars =20 μm. The bars indicate the means ± the standard errors of the means; *, p < 0.05, relative
to the MCAO group
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Fig. 5 Expression levels of SYN (SYN-1), GAP-43 and MAP-2 in all groups at each time point. The proteins expression levels at each time point
following the MCAO are presented in representative western-blotting autoradiograms (a). We detected SYN at 77 kDa, GAP-43 at 48 kDa, MAP-2
at 70 kDa and the β-actin loading control at 43 kDa. Lane 1, sham group; Lane 2, MCAO group; Lane 3, MCAO + BYHWD group; Lane 4,
MCAO + PE group; Lane 5, MCAO + BYHWD + PE group. The quantitative analyses (n = 6) of the western blot results for the expression levels of
SYN, GAP-43 and MAP-2 are presented in the bar graphs (b). The bars indicate the means ± standard errors of the means. *, p < 0.05, compared
to the MCAO group
Fig. 6 TEM micrograms. Representative synapse ultrastructures of all groups. An intact synaptic ultrastructure is shown in panel sham, and a
disorderly synaptic ultrastructure is illustrated in panels MCAO, MCAO + BYHWD, MCAO + PE and MCAO + BYHWD + PE. The arrowheads presented
in panels MCAO, MCAO + BYHWD, MCAO + PE and MCAO + BYHWD + PE indicate the synaptic disruptions. Scale bars =200 nm
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neurological deficits after MCAO induction [34, 35].
We found that the neurological deficits of the combin-
ation treatment group was similar to that of the other
MCAO groups on Day 3 after the MCAO induction. It
was remarkably alleviated on Day 7 and 14 post-
ischemia, compared to the MCAO rats without treat-
ment. This result indicates that BYHWD effectively
facilitated the effects of the physical exercise after a
cerebral ischemia insult.
SYN (SYN-1), GAP-43 and MAP-2 are associated with
presynaptic and postsynaptic plasticity as well as the
neuronal cytoskeleton [6, 38, 47, 48]. The synaptic plas-
ticity markers SYN (SYN-1), GAP-43 and MAP-2 are
up-regulated in the post-ischemic milieu, thus, they were
postulated to play pivotal roles in neurorehabilitation
[49–53]. We qualitatively analyzed these 3 proteins to
determine the effects of the combination therapy of
BYHWD and physical exercise on synaptic plasticity.
The immunohistochemical data suggested that BYHWD
or physical exercise alone can ameliorate the disruption
of these 3 synaptic proteins that was induced by the
MCAO induction. However, the effects of the individual
treatments were not significant, while the combination
treatment was. Furthermore, we quantitatively analyzed
the changes of these 3 proteins with various treatment
modalities using western blot. The combination of the
BYHWD and physical exercise treatment alleviated the
decreases in the SYN, GAP-43 and MAP-2 proteins after
the cerebral ischemia. These changes were consistent
with the neurological deficits in the various groups
after the MCAO induction. It was reported that there
were differences in synaptic change over time [54].
Otherwise, we did not identify significant differences in
SYN (SYN-1), GAP-43 and MAP-2 protein levels on
each time point (p > 0.05). Similarly, the time-
dependent synaptic change did not relate to each kind
of synaptic junctions [55].
In this study, we assessed the synaptic ultrastruc-
ture of all groups on Day 14 post-cerebral ischemia
using TEM. We found a clear and intact synaptic
ultrastructure in the high magnification micrographs
from sham group, and a disorganized synaptic ultra-
structure in all the MCAO groups (Fig. 6). The syn-
aptic disorganization was markedly ameliorated in
the group that received the combination treatment
of BYHWD and physical exercise.
Conclusions
In summary, we conclude that BYHWD could be a po-
tential therapeutic pharmaceutical approach, which
can effectively facilitate neurorehabilitation following
cerebral ischemia insult through improved synaptic
plasticity.
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